• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

    2/12/24 10:06:24 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    SC 13G/A 1 tm245889d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    Brainstorm Cell Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.00005 par value

    (Title of Class of Securities)

     

    10501E 201

    (CUSIP Number)

     

    Febuary 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)
    x   Rule 13d-1(c)
    ¨   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 10501E 201

     

    1.  

    Names of Reporting Persons

    Kevin D. Ness 

     

    2.   Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)   ¨
        (b)  

    ¨

     

    3.  

    SEC Use Only

     

    4.   Citizenship or Place of Organization
    Canada 

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

     

    6.

    Shared Voting Power

    3,060,000 (1)

     

    7.

    Sole Dispositive Power

    0

     

    8.

    Shared Dispositive Power

    3,060,000 (1)

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,060,000 (1) 

     

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    6.25% (2)

     

    12.  

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Consists of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power.

     

    (2)

    Percentage of class is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    1

     

    CUSIP No. 10501E 201

     

    Item 1.    
      (a) Name of Issuer
       

    Brainstorm Cell Therapeutics Inc.

     

      (b) Address of Issuer's Principal Executive Offices
        1325 Avenue of Americas, 28th Floor, New York, NY 10019
         
    Item 2.    
      (a) Name of Persons Filing
        Kevin D. Ness (the “Reporting Person”)
         
      (b) Address of Principal Business Office or, if none, Residence
       

    The principal business address for the Reporting Person is:

    2121 N. California Blvd., Suite 610

    Walnut Creek, CA 94596

     

      (c) Citizenship
       

    The Reporting Person is a citizen of Canada.

     

      (d) Title of Class of Securities
       

    Common Stock, $0.00005 par value

     

      (e) CUSIP No.
       

    10501E 201

     

    Item 3.   If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
        Not Applicable

     

    Item 4.

     

    Ownership

       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
    Item 1.

     

      (a)

    Amount beneficially owned:

    3,060,000 shares of Common Stock

     

      (b) Percent of class: 6.25%

     

      (c) Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    0 shares of Common Stock

     

      (ii)

    Shared power to vote or to direct the vote:

    3,060,000 shares

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    0 shares of Common Stock

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    3,060,000 shares

     

    2

     

    CUSIP No. 10501E 201

     

    The securities reported above consist of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power. The reported beneficial ownership percentage is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    Item 5. Ownership of Five Percent or Less of a Class
      Not Applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
      Not Applicable.
       
    Item 10. Certification
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.

     

    3

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: Febuary 8, 2024

     

      Kevin D. Ness
           
      By:    /s/ Kevin D. Ness
          Name: Kevin D. Ness

     

    4

     

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    10/2/24 8:00:14 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

    4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    7/31/24 4:09:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

    4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    7/31/24 4:08:32 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pitts Peter Joe

    3 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    6/3/26 5:37:34 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Lebovits Chaim was granted 1,800,000 shares, increasing direct ownership by 896% to 2,000,960 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    5/29/26 5:02:36 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP & Chief Business Officer Yablonka Uri was granted 150,000 shares, increasing direct ownership by 219% to 218,464 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    5/29/26 5:02:01 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    SEC Filings

    View All

    SEC Form EFFECT filed by Brainstorm Cell Therapeutics Inc.

    EFFECT - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    6/3/26 12:15:31 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    5/28/26 4:05:29 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    5/15/26 5:00:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

    Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicineNEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the u

    6/2/26 9:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

    Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol AssessmentNEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and U.S. Food and Drug Administration (FDA) governance. He previously served as A

    5/28/26 7:45:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

    $2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE TrialNEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing:The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of t

    5/19/26 8:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainstorm Cell upgraded by Maxim Group

    Maxim Group upgraded Brainstorm Cell from Hold to Buy

    2/5/21 8:55:41 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

    Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

    2/4/21 1:51:23 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

    Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol AssessmentNEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and U.S. Food and Drug Administration (FDA) governance. He previously served as A

    5/28/26 7:45:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

    Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

    6/20/24 6:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

    Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

    7/12/23 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confir

    8/14/25 7:02:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

    Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call.  Following the

    8/8/25 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/14/24 3:24:53 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/13/24 7:55:51 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

    SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    2/12/24 10:06:24 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care